Recombinant Rhesus Macaque ACTL6A Protein, His (Fc)-Avi-tagged
Cat.No. : | ACTL6A-50R |
Product Overview : | Recombinant Rhesus Macaque ACTL6A with His (Fc)-Avi tag was expressed and purified |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Rhesus Macaque |
Tag : | His&Fc&Avi |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method |
Purity : | ≥85% by SDS-PAGE |
Stability : | Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. |
Storage : | For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
Storage Buffer : | PBS buffer |
Gene Name : | ACTL6A actin-like 6A [ Macaca mulatta (Rhesus monkey) ] |
Official Symbol : | ACTL6A |
Synonyms : | ACTL6A; actin-like protein 6A; |
Gene ID : | 708935 |
mRNA Refseq : | NM_001104559 |
Protein Refseq : | NP_001098029 |
UniProt ID : | F6ZQD7 |
Products Types
◆ Recombinant Protein | ||
Actl6a-1515M | Recombinant Mouse Actl6a Protein, Myc/DDK-tagged | +Inquiry |
ACTL6A-222H | Recombinant Human ACTL6A Protein, GST-tagged | +Inquiry |
ACTL6A-61H | Recombinant Human Actin-like 6A, T7-tagged | +Inquiry |
ACTL6A-9514Z | Recombinant Zebrafish ACTL6A | +Inquiry |
ACTL6A-220H | Recombinant Human ACTL6A Protein, GST-tagged | +Inquiry |
◆ Lysates | ||
ACTL6A-9061HCL | Recombinant Human ACTL6A 293 Cell Lysate | +Inquiry |
ACTL6A-9062HCL | Recombinant Human ACTL6A 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (5)
Write a reviewExtensive quality control measures, including rigorous testing for activity, stability, and functionality, ensure that the protein product meets the highest standards of quality.
Stringent quality control protocols are followed during the production process, ensuring the protein's consistent performance and characteristics.
The company's customer support team is highly responsive and knowledgeable, promptly addressing any inquiries or concerns we have regarding the protein product.
We have observed significant improvements in experimental outcomes
We have consistently received our orders on time, with efficient shipping and reliable tracking information provided by the company.
Q&As (21)
Ask a questionCTL6A plays a critical role in promoting metastasis and epithelial-to-mesenchymal transition (EMT) in hepatocellular carcinoma, processes associated with cancer progression and invasion.
Yes, based on its pro-tumor function and role as an EMT activator in colon cancer, ACTL6A may serve as a potential therapeutic target for developing novel treatment strategies.
The specific molecular pathways and mechanisms through which ACTL6A promotes tumor progression and activates EMT in hepatocellular carcinoma and colon cancer are still under investigation.
Elevated ACTL6A levels in cancer cells suggest its potential role as a driver in promoting cancer cell survival and tumor formation.
Actl6a's role as a gatekeeper in mESCs is to prevent the cells from differentiating into the PrE lineage, ensuring the maintenance of their pluripotency and self-renewal capabilities.
In colon cancer, ACTL6A functions as an activator of epithelial-to-mesenchymal transition (EMT), a process that contributes to cancer cell invasion, metastasis, and drug resistance.
In hepatocellular carcinoma, ACTL6A is involved in metastasis and epithelial-to-mesenchymal transition (EMT). In colon cancer, ACTL6A acts as an EMT activator, exhibiting pro-tumor function.
ACTL6A is vital for embryogenesis and differentiation processes, playing crucial roles in the development of various tissues and organs during embryonic development.
The discovery of Actl6a's role as a gatekeeper in preventing mESCs from entering the PrE lineage expands our understanding of the regulatory mechanisms underlying cell fate decisions in embryonic stem cells.
ACTL6A has been identified as a central oncogenic driver in various tumor types beyond esophageal squamous cell carcinoma, suggesting its broad significance in cancer development and progression.
By identifying ACTL6A as a potential therapeutic target, it suggests the possibility of developing alternative treatment strategies specifically for ESCC, potentially leading to improved therapeutic outcomes.
ACTL6A's functional roles beyond its involvement in chromatin remodeling and tumor development are still under investigation.
ACTL6A suppresses p21Cip1 promoter activity, leading to reduced p21Cip1 protein levels in aggressive mesothelioma cells.
Actl6a demonstrates a Yin/Yang regulating pattern by repressing the expression of PrE regulators while maintaining the expression of pluripotency-related genes, maintaining a balance between differentiation and pluripotency in mESCs.
ACTL6A and p63 collaborate as oncogenic drivers in HNSCC, suggesting their combined role in promoting the development and progression of this type of cancer.
The SWI/SNF complexes are involved in regulating gene expression by remodeling chromatin structure. ACTL6A acts as a regulatory subunit within these complexes, contributing to their activity and function.
Actl6a is a subunit of complexes such as esBAF, INO80, and Tip60-p400, which play crucial roles in maintaining the pluripotency and self-renewal of embryonic stem cells.
Actl6a's presence in complexes such as esBAF, INO80, and Tip60-p400 suggests its multifaceted involvement in chromatin remodeling and gene regulation, which are crucial for the maintenance of embryonic stem cells.
Actl6a targets the promoters of key PrE regulators, such as Sall4 and Fgf4, and represses their expression, thereby inhibiting PrE differentiation in embryonic stem cells.
The crucial role of ACTL6A in DNA replication and the ATR-Chk1 pathway in glioblastoma, indicating that it could serve as a potential therapeutic target for intervention in this type of cancer.
ACTL6A expression influences ESCC cell cycle redistribution by activating the S6K1/pS6 pathway, which plays a role in regulating cell cycle progression and proliferation.
Ask a Question for All ACTL6A Products
Required fields are marked with *
My Review for All ACTL6A Products
Required fields are marked with *
Inquiry Basket